Clinical trial
The Effect Of Dose Titration And Dose Tapering On The Tolerability Of DVS SR In…
NCT00401245 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00401245 |
|---|---|
| Title | The Effect Of Dose Titration And Dose Tapering On The Tolerability Of DVS SR In Women With Vasomotor Symptoms |
| Official title | The Effect of Dose Titration and Dose Tapering on the Tolerability of DVS SR in Women With Vasomotor Symptoms Associated With Menopause: The PRIMMUS (PRIstiq for Managing Menopause and Understanding Symptoms) Study |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Vasomotor Symptoms |
| Intervention type | Drug |
| Interventions | desvenlafaxine succinate sustained release, Placebo |
| Enrollment | 500 |
| Start date | Dec 1, 2006 |
| Primary completion | Jan 1, 2008 |
| Completion | Jan 1, 2008 |
| First posted | Nov 20, 2006 |
| Last update posted | Oct 26, 2011 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: